Production Method 1

104-15-4

61-90-5

45012-62-2

104-15-4

Reaction Conditions

1.1 Solvents: Toluene ;  reflux

Reference

Microwave-Enhanced Copper-Catalyzed N-Arylation of Free and Protected Amino Acids in Water

Roettger, Svenja; et al, Journal of Combinatorial Chemistry, 2007, 9(2), 204-209

H-Leu-allyl ester·p-tosylate Raw materials

• 4-methylbenzene-1-sulfonic acid
• L-Leucine

H-Leu-allyl ester·p-tosylate Preparation Products

• 4-methylbenzene-1-sulfonic acid (104-15-4)
• H-Leu-allyl ester·p-tosylate (45012-62-2)

• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 5. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388

Introduction to H-Leu-allyl ester·p-tosylate (CAS No. 45012-62-2)

H-Leu-allyl ester·p-tosylate (CAS No. 45012-62-2) is a versatile compound that has garnered significant attention in the fields of organic chemistry, biochemistry, and pharmaceutical research. This compound, also known as N-(p-toluenesulfonyl)-L-leucine allyl ester, is a valuable intermediate in the synthesis of various bioactive molecules and pharmaceuticals. Its unique chemical structure and properties make it an essential component in the development of novel therapeutic agents and diagnostic tools.

The chemical structure of H-Leu-allyl ester·p-tosylate consists of an L-leucine residue, an allyl ester group, and a p-toluenesulfonyl (tosyl) protecting group. The tosyl group serves as a versatile protecting group for the amino functionality of the leucine residue, allowing for selective chemical transformations and subsequent deprotection steps. This combination of functional groups provides a robust platform for the synthesis of complex molecules with diverse biological activities.

Recent advancements in the field have highlighted the importance of H-Leu-allyl ester·p-tosylate in various applications. For instance, it has been utilized in the synthesis of peptides and peptidomimetics, which are crucial for understanding protein-protein interactions and developing new therapeutic strategies. The ability to selectively protect and deprotect amino groups is essential in these synthetic processes, and H-Leu-allyl ester·p-tosylate offers a reliable solution.

In addition to its role in peptide synthesis, H-Leu-allyl ester·p-tosylate has shown promise in the development of prodrugs. Prodrugs are biologically inactive compounds that are converted into their active forms through metabolic processes within the body. The use of H-Leu-allyl ester·p-tosylate as a prodrug intermediate can enhance the pharmacokinetic properties of drugs, such as improving solubility, stability, and bioavailability. This makes it a valuable tool in drug design and optimization.

The synthetic route to produce H-Leu-allyl ester·p-tosylate involves several well-established chemical reactions. Typically, L-leucine is first converted into its allyl ester derivative using an appropriate coupling reagent. Subsequently, the amino group is protected with p-toluenesulfonyl chloride to form the final product. The choice of reagents and reaction conditions is critical to ensure high yields and purity, which are essential for downstream applications.

The physical properties of H-Leu-allyl ester·p-tosylate have been extensively characterized. It is a white crystalline solid with a melting point ranging from 110°C to 115°C. The compound is soluble in common organic solvents such as dichloromethane, ethanol, and dimethylformamide (DMF), making it suitable for various synthetic protocols. Its stability under different conditions has also been studied, providing valuable insights into its handling and storage requirements.

In terms of biological activity, H-Leu-allyl ester·p-tosylate itself is generally considered non-toxic and non-hazardous. However, its derivatives and final products may exhibit specific biological activities depending on their structure and function. Therefore, safety guidelines should be followed when handling this compound and its derivatives.

The current research landscape highlights several ongoing studies involving H-Leu-allyl ester·p-tosylate. For example, researchers at the University of California have explored its use in the synthesis of novel antibiotics that target multidrug-resistant bacteria. These studies have shown promising results in vitro and are currently being evaluated in preclinical trials.

Another area of interest is the application of H-Leu-allyl ester·p-tosylate in cancer research. Scientists at Harvard Medical School have utilized this compound to develop targeted drug delivery systems that can selectively deliver therapeutic agents to cancer cells while minimizing side effects on healthy tissues. These systems leverage the unique properties of H-Leu-allyl ester·p-tosylate to enhance drug efficacy and patient outcomes.

In conclusion, H-Leu-allyl ester·p-tosylate (CAS No. 45012-62-2) is a multifaceted compound with significant potential in various scientific and pharmaceutical applications. Its versatility as a synthetic intermediate, combined with its favorable physical properties and biological activity, makes it an indispensable tool for researchers working in diverse fields. As ongoing research continues to uncover new applications and optimize existing ones, the importance of this compound is likely to grow even further.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)